SL-172154 + Azacitidine (AZA) + Venetoclax
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Trial Timeline
Mar 17, 2022 → Feb 6, 2025
NCT ID
NCT05275439About SL-172154 + Azacitidine (AZA) + Venetoclax
SL-172154 + Azacitidine (AZA) + Venetoclax is a phase 1 stage product being developed by Shattuck Labs for Acute Myeloid Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05275439. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndromes.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05275439 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia